No Data
No Data
Express News | Unicycive Therapeutics Shares Are Trading Higher After the United States Patent and Trademark Office Granted the Company a Patent on UNI-494 to Treat Acute Kidney Injury
Unicycive Secures Patent for Kidney Disease Treatment UNI-494, Valid Until 2040
Express News | Unicycive Therapeutics Inc - Patent, Valid Until 2040
Express News | Unicycive Therapeutics Granted Patent on Uni-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (Uspto)
Maxim Group Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $4
Buy Rating Affirmed for Unicycive Therapeutics Amid Positive Clinical Feedback and Strong Market Entry Potential
No Data